Company intelligence / Profile preview

S-Evans Biosciences

Hangzhou, Zhejiang Province, Chinacmocro.com ↗

Ownership: Private
Development stage: Clinical

Overview

The company had IND approval for human cord-derived MSC cell therapy for inflammatory bowel diseases and atopic dermatitis. They were also developing menstrual blood-derived stem cells for hepatic infarction

Therapeutic areas: GastroenterologyDermatology
Modalities: Mesenchymal stem cell therapyMenstrual stem cells (MenSCs)
Industry: Biotech

Drug pipeline

3 assets

SM-hUCMSC secretome

2 more assets in the full pipeline.

Request access →

Partnerships

Cryo-Cell International, Inc.

Beyond the preview

Go deeper on S-Evans Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-Evans Biosciences.

Explore the full profile